We are live on ! Find out more
CLLS

Cellectis

27 hedge funds and large institutions have $18.3M invested in Cellectis in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.18% less ownership

Funds ownership: 13.73%13.56% (-0.18%)

13% less funds holding

Funds holding: 3127 (-4)

30% less capital invested

Capital invested by funds: $26.1M → $18.3M (-$7.84M)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

76% less call options, than puts

Call options by funds: $8K | Put options by funds: $33K

Holders
27
Holders Change
-4
Holders Change %
-12.9%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
4
Reduced
6
Closed
7
Calls
$8K
Puts
$33K
Net Calls
-$25K
Net Calls Change
+$40K

CLLS Hedge Fund Activity: Q2 2024 in Review

27 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q2 2024, worth a combined $18.3M — down 30% from $26.1M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of CLLS and 4 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 4 added.

The largest buyer was UBS AM, opening a new position worth an estimated $3.77M. The largest seller was Oppenheimer & Co, exiting entirely with an estimated $355K sold.

  • 27 institutional investors held Cellectis (CLLS) as of Q2 2024, down from 31 in Q1 2024.
  • Funds reported $18.3M of Cellectis stock for Q2 2024, down 30% quarter-over-quarter.
  • 4 funds opened new Cellectis positions in Q2 2024 and 7 closed out, a net change of -3 holders.
  • The largest Cellectis buyer in Q2 2024 was UBS AM, an estimated $3.77M added.
  • The largest Cellectis seller in Q2 2024 was Oppenheimer & Co, an estimated $355K sold.

Based on aggregated 13F filings for Q2 2024.